BG103674A - Polymorphous form of zopolrestatmonohydrate - Google Patents

Polymorphous form of zopolrestatmonohydrate

Info

Publication number
BG103674A
BG103674A BG103674A BG10367499A BG103674A BG 103674 A BG103674 A BG 103674A BG 103674 A BG103674 A BG 103674A BG 10367499 A BG10367499 A BG 10367499A BG 103674 A BG103674 A BG 103674A
Authority
BG
Bulgaria
Prior art keywords
zopolrestatmonohydrate
methods
relates
forms
polymorphous form
Prior art date
Application number
BG103674A
Other languages
Bulgarian (bg)
English (en)
Inventor
John Lambert
Timothy Norris
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG103674A publication Critical patent/BG103674A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG103674A 1998-08-21 1999-08-20 Polymorphous form of zopolrestatmonohydrate BG103674A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9747498P 1998-08-21 1998-08-21

Publications (1)

Publication Number Publication Date
BG103674A true BG103674A (en) 2000-03-31

Family

ID=22263562

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103674A BG103674A (en) 1998-08-21 1999-08-20 Polymorphous form of zopolrestatmonohydrate

Country Status (31)

Country Link
US (1) US6159976A (xx)
EP (1) EP0982306A3 (xx)
JP (1) JP2000072769A (xx)
KR (1) KR20000017411A (xx)
CN (1) CN1245804A (xx)
AP (1) AP9901662A0 (xx)
AU (1) AU4453299A (xx)
BG (1) BG103674A (xx)
BR (1) BR9903873A (xx)
CA (1) CA2280590A1 (xx)
EA (1) EA199900675A3 (xx)
EE (1) EE9900385A (xx)
GT (1) GT199900137A (xx)
HR (1) HRP990259A2 (xx)
HU (1) HUP9902783A3 (xx)
ID (1) ID23307A (xx)
IL (1) IL131419A0 (xx)
IS (1) IS5155A (xx)
MA (1) MA26678A1 (xx)
NO (1) NO994027L (xx)
NZ (1) NZ337363A (xx)
OA (1) OA11150A (xx)
PA (1) PA8480601A1 (xx)
PE (1) PE20000993A1 (xx)
PL (1) PL335016A1 (xx)
SG (1) SG83147A1 (xx)
TN (1) TNSN99159A1 (xx)
TR (1) TR199901996A2 (xx)
UY (1) UY25668A1 (xx)
YU (1) YU39899A (xx)
ZA (1) ZA995297B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5934206B2 (ja) 2010-07-16 2016-06-15 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク アルドース還元酵素阻害剤および同使用方法
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
US20140228319A1 (en) * 2013-02-13 2014-08-14 Banavara L. Mylari Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
ES2836500T3 (es) 2016-06-21 2021-06-25 Univ Columbia Inhibidores de aldosa reductasa y métodos de uso de los mismos
US11590131B2 (en) 2017-07-28 2023-02-28 Applied Therapeutics, Inc. Compositions and methods for treating galactosemia
SG11202110590PA (en) 2019-04-01 2021-10-28 Applied Therapeutics Inc Inhibitors of aldose reductase
WO2021202523A1 (en) 2020-03-31 2021-10-07 Applied Therapeutics, Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
CN115996725A (zh) 2020-05-01 2023-04-21 应用治疗公司 用于治疗山梨糖醇脱氢酶缺乏症的醛糖还原酶抑制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4748280A (en) * 1985-11-07 1988-05-31 Pfizer Inc. Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
WO1992003432A1 (en) * 1990-08-28 1992-03-05 Pfizer Inc. 3-(5-trifluoromethylbenzothiazol-2-ylmethyl)-4-oxo-3h-phythalazin-1-ylacetic acid monohydrate
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
US6127367A (en) * 1996-02-29 2000-10-03 Pfizer, Inc. Method of reducing tissue damage associated with non-cardiac ischemia

Also Published As

Publication number Publication date
HUP9902783A2 (hu) 2000-12-28
CA2280590A1 (en) 2000-02-21
PA8480601A1 (es) 2000-09-29
EP0982306A3 (en) 2000-07-05
BR9903873A (pt) 2000-09-19
AU4453299A (en) 2000-03-09
EA199900675A2 (ru) 2000-02-28
TNSN99159A1 (fr) 2005-11-10
OA11150A (en) 2003-04-16
EA199900675A3 (ru) 2000-06-26
TR199901996A2 (xx) 2000-03-21
AP9901662A0 (en) 1999-09-30
KR20000017411A (ko) 2000-03-25
YU39899A (sh) 2002-12-10
PE20000993A1 (es) 2000-10-04
IL131419A0 (en) 2001-01-28
ZA995297B (en) 2001-02-19
NO994027D0 (no) 1999-08-20
NO994027L (no) 2000-02-22
PL335016A1 (en) 2000-02-28
EE9900385A (et) 2000-04-17
UY25668A1 (es) 2001-08-27
MA26678A1 (fr) 2004-12-20
US6159976A (en) 2000-12-12
NZ337363A (en) 2001-01-26
CN1245804A (zh) 2000-03-01
GT199900137A (es) 2001-02-09
ID23307A (id) 2000-04-05
JP2000072769A (ja) 2000-03-07
IS5155A (is) 2000-02-22
HUP9902783A3 (en) 2001-01-29
SG83147A1 (en) 2001-09-18
EP0982306A2 (en) 2000-03-01
HU9902783D0 (en) 1999-10-28
HRP990259A2 (en) 2000-06-30

Similar Documents

Publication Publication Date Title
WO2002014252A3 (en) Compositions containing hypoglycemically active stilbenoids
HK1034909A1 (en) Novel fatty analogues for the treatment of diabetes
WO2002013811A3 (en) Compositions containing hypoglycemically active stilbenoids
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
MXPA02011632A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
MA27551A1 (fr) Composition immunogene
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
ATE312190T1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
MXPA04004779A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
WO2002051363A3 (en) Absorbent articles with simplified compositions having good stability
HK1071521A1 (en) Use of a composition comprising cis-clomiphene andtrans-clomiphene in the preparation of a medicament for increasing serum levels of testosterone
BG103674A (en) Polymorphous form of zopolrestatmonohydrate
EP1077218A3 (en) Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
RS44204A (xx) Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
ATE188869T1 (de) Stabilisiertes sonnenschutzmittel
BR9805626A (pt) Combinação , composição cosmética, uso de pelo menos um poliol e processo para estabilizar a procisteìna em uma composição doméstica.
RS44304A (xx) Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
BR0007989A (pt) Composição para o tratamento de cabelo
EP1156058A3 (en) Process for the preparation of (E,Z) 3-(2-aminoethoxyimino)-androstane-6,17-dione and its analogues
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
EP1121932A4 (en) DRUGS FOR EYE DISEASES
WO1999058098A3 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
WO2004050123A3 (en) Concentrated liquid valdecoxib composition
WO1999048851A3 (en) Processes for preparing intermediates
WO2001051489A3 (en) Methods for lowering uric acid levels